STAT6
Inflammatory Diseases (e.g., type 2 inflammation)
Pre-clinicalActive
Key Facts
Indication
Inflammatory Diseases (e.g., type 2 inflammation)
Phase
Pre-clinical
Status
Active
Company
About Recludix Pharma
Recludix Pharma is a private, pre-clinical stage biotech leveraging a proprietary, integrated drug discovery platform to target previously undruggable protein domains, specifically SH2 domains. The company's platform combines custom DNA-encoded libraries, massively parallel structure-activity relationship determination, and a selectivity screening tool to develop novel therapeutics for inflammatory and oncological diseases. Led by industry veterans from companies like Seagen and Blueprint Medicines, Recludix is advancing a pipeline with initial programs targeting STAT6 and BTK, aiming to address significant unmet medical needs in immunology and oncology.
View full company profile